TRENTAL is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. TRENTAL can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.

The usual dosage of TRENTAL in controlled-release tablet form is one tablet (400 mg) three times a day with meals.
While the effect of TRENTAL may be seen within 2 to 4 weeks, it is recommended that treatment be continued for at least 8 weeks. Efficacy has been demonstrated in double-blind clinical studies of 6 months duration.
Digestive and central nervous system side effects are dose related. If patients develop these effects it is recommended that the dosage be lowered to one tablet twice a day (800 mg/day). If side effects persist at this lower dosage, the administration of TRENTAL should be discontinued.

TRENTAL (pentoxifylline) is available for oral administration as 400 mg pink film-coated oblong tablets imprinted Trental®; supplied in bottles of 100 (NDC 0039-0078-10), and Unit Dose Packs of 100 (NDC 0039-0078-11). Store between 59 and 86° F (15 and 30° C). Dispense in well-closed, light-resistant containers. Protect blisters from light.

Rx only.
Rev. May 2003

US Patents 3,737,433 & 4,189,469
US Patent 3,737,433 patent term has been extended.

Manufactured by:
Patheon Pharmaceuticals Inc.
Cincinnati, OH 45215 USA

Manufactured for:
Aventis Pharmaceuticals NJ
Bridgewater, NJ 08807 USA

©2002 Aventis Pharmaceuticals Inc.

TRE-MAY03-F-A
Revised April 2005

Bookmark this page: